Literature DB >> 9207196

Cleavage specificity of human rhinovirus-2 2A protease for peptide substrates.

Q M Wang1, W Sommergruber, R B Johnson.   

Abstract

Substrate requirements of the human rhinovirus serotype-2 2A protease have been examined using synthetic peptides. A chromogenic peptide with a sequence of TRPIITTA-p-nitroanilide was found to be cleaved efficiently by the 2A protease with an apparent Km value of 95 microM, which allowed the protease activity to be monitored and measured continuously using a spectrophotometer. Competition cleavage assays reveal this peptide was cleaved over 10-fold more efficiently than the 16-mer peptide derived directly from its native processing site. On the basis of these data, we conclude that the P1' glycine residue is not absolutely needed for the 2A cleavage to occur and the essential residues required for the 2A activity would exist within the N-terminal side of the scissile bond.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207196     DOI: 10.1006/bbrc.1997.6830

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides.

Authors:  Q M Wang; R B Johnson; L N Jungheim; J D Cohen; E C Villarreal
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Enzymatic characterization of refolded human rhinovirus type 14 2A protease expressed in Escherichia coli.

Authors:  Q M Wang; R B Johnson; G A Cox; E C Villarreal; L M Churgay; J E Hale
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

3.  Genetic selection of poliovirus 2Apro-binding peptides.

Authors:  I Ventoso; A Barco; L Carrasco
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses.

Authors:  Bei Wang; Xueyan Xi; Xiaobo Lei; Xiaoyan Zhang; Sheng Cui; Jianwei Wang; Qi Jin; Zhendong Zhao
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.